Biography
Dr. Kamath is a founding scientist at Serimmune, Inc. Her expertise in therapeutic and diagnostic development has been essential to Serimmune’s Serum Epitope Repertoire Analysis (SERA) platform. SERA combines the power of bacterial display peptide library technology with next-generation sequencing and bioinformatics to profile antibody repertoires and identify and map antibody-based biomarkers of infections, autoimmunity and cancer. Once discovered, all the biomarkers can be assayed simultaneously from a single test, potentially reducing time to diagnosis or providing insights into the cause of undiagnosed disease. Prior to her work at Serimmune, Dr. Kamath worked on the development of cancer companion diagnostic and diagnostic assays at Agilent Technologies as well as modified therapeutic monoclonal antibodies (ProbodiesTM) at CytomX Therapeutics. She received her Ph.D. from University of California, Santa Barbara with an emphasis on cancer biology and therapy.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.
Sessions: